The Association of Shelter Veterinarians veterinary medical care guidelines for spay-neuter programs.

As efforts to reduce the overpopulation and euthanasia of unwanted and unowned dogs and cats have increased, greater attention has been focused on spay-neuter programs throughout the United States. Because of the wide range of geographic and demographic needs, a wide variety of programs have been developed to increase delivery of spay-neuter services to targeted populations of animals, including stationary and mobile clinics, MASH-style operations, shelter services, feral cat programs, and services provided through private practitioners. In an effort to ensure a consistent level of care, the Association of Shelter Veterinarians convened a task force of veterinarians to develop veterinary medical care guidelines for spay-neuter programs. The guidelines consist of recommendations for preoperative care (eg, patient transport and housing, patient selection, client communication, record keeping, and medical considerations), anesthetic management (eg, equipment, monitoring, perioperative considerations, anesthetic protocols, and emergency preparedness), surgical care (eg, operating-area environment; surgical-pack preparation; patient preparation; surgeon preparation; surgical procedures for pediatric, juvenile, and adult patients; and identification of neutered animals), and postoperative care (eg, analgesia, recovery, and release). These guidelines are based on current principles of anesthesiology, critical care medicine, microbiology, and surgical practice, as determined from published evidence and expert opinion. They represent acceptable practices that are attainable in spay-neuter programs.

The Association of Shelter Veterinarians' 2016 Veterinary Medical Care Guidelines for Spay-Neuter Programs.

As community efforts to reduce the overpopulation and euthanasia of unwanted and unowned cats and dogs have increased, many veterinarians have increasingly focused their clinical efforts on the provision of spay-neuter services. Because of the wide range of geographic and demographic needs, a wide variety of spay-neuter programs have been developed to increase delivery of services to targeted populations of animals, including stationary and mobile clinics, MASH-style operations, shelter services, community cat programs, and services provided through private practitioners. In an effort to promote consistent, high-quality care across the broad range of these programs, the Association of Shelter Veterinarians convened a task force of veterinarians to develop veterinary medical care guidelines for spay-neuter programs. These guidelines consist of recommendations for general patient care and clinical procedures, preoperative care, anesthetic management, surgical procedures, postoperative care, and operations management. They were based on current principles of anesthesiology, critical care medicine, infection control, and surgical practice, as determined from published evidence and expert opinion. They represent acceptable practices that are attainable in spay-neuter programs regardless of location, facility, or type of program. The Association of Shelter Veterinarians envisions that these guidelines will be used by the profession to maintain consistent veterinary medical care in all settings where spay-neuter services are provided and to promote these services as a means of reducing sheltering and euthanasia of cats and dogs.

Treatment of cutaneous T-cell lymphoma with dacarbazine in a dog.

Abstract Epitheliotropic cutaneous T-cell lymphoma in a Lhasa Apso dog treated with dacarbazine is reported. Clinical disease consisted of a 4 × 4-cm ulcerated mass over the mandibular symphysis and bilateral lymphadenopathy of the submandibular lymph nodes. Skin biopsy sections were díagnostic for epitheliotropic cutaneous T-cell lymphoma, and immunohistochemistry staining for the CD3 antigen was positive. Tissue samples were submitted for chemosensitivity testing and dacarbazine was shown to be 60% effective. Treatment with dacarbazine resulted in total clinical remission. The dog remains disease free 1 year after treatment. Résumé- Les auteurs décrivent un cas de lymphome cutané T épithéliotrope chez un Lhassa Apso traitéà la dacarbazine. Le tableau clinique était caractérisé par la présence d'une masse ulcérée de 4 × 4 cm sur la symphyse mandibulaire et par une adénopathie bilatérale des ganglions sous mandibulaires. Les biopsies posèrent le díagnostic de lymphome cutané T et l'immunomarquage fut positif pour l'antigène CD3. Des prélèvements tissulaires fürent soumis à des tests de chimiosensibilité et la dacarbazine se révéla efficace à 60%. Le traitement à la dacarbazine entraina une rémission clinique totale. Le chien ne présente pas de récidive un an après le traitement. [Lemarié, S. L., Eddlestone, S. M. Treatment of cutaneous T-cell lymphoma with dacarbazine in a dog. (Traitement d'un lymphome cutané T à la dacarbazine chez un chien.) Veterinary Dermatology 1997; 8: 41-46.] Resumen Se describe el tratamiento con dacarbazina de un linfoma cutáneo epiteliotrópico de células T en un Lasha Apso. La presentación clinica consistia en una masa ulcerada de 4 × 4 cm por encima de la sinfisis mandibular y linfadenopatia bilateral de los ganglios linfáticos submandibulares. El estudio histológico cutáneo permitió un díagnóstico de linfoma cutáneo epiteliotrópico de celulas T, con positividad inmunohistoquimica al antigeno CD3. Se remitieron muestras tisulares para pruebas de quimiosensibilidad, en las que la dacarbazina mostró una efectividad del 60%. El tratamiento con dacarbazina llevó a una remisión clinica total. El perro sigue sano un año después del tratamiento. [Lemarié, S. L., Eddlestone, S. M. Treatment of cutaneous T-cell lymphoma with dacarbazine in a dog. (Tratamiento del linfoma cutáneo de celulas T con dacarbazina en un perro.) Veterinary Dermatology 1997; 8: 41-46.] Zusammenfassung- Es wird über eine epitheliotropes kutanes T-Zell-Lymphom bei einem Lhasa Apso berichtet, das mit Dacarbazin behandelt wurde. Die klinische Erkrankung bestand in einer 4 × 4 cm großen ulzerierten Masse über der Symphyse der Mandibula sowie einer bilateralen Lymphadenopathie der submandibulären Lymphknoten. Die Hautbiopsien ergaben die Diagnose epitheliotropes kutanes T-Zell-Lymphom, die immunohistochemische Färbung auf CD3-Antigen fiel positiv aus. Die Gewebsproben wurden einer Chemosensitivitätsprobe unterzogen und Dacarbazin erwies sich zu 60% wirksam. Die Behandlung mit Dacarbazin führte zu einer vollständigen klinischen Remission. Der Hund blieb frei von Krankheitssymptomen seit einem Jahr nach der Behandlung. [Lemarié, S. L., Eddlestone, S. M. Treatment of cutaneous T-cell lymphoma with dacarbazine in a dog. (Die Behandlung eines kutanen T-Zell-Lymphom mit Dacarbazin bei einem Hund.) Veterinary Dermatology 1997; 8: 41-46.].